12,180.3573.45
Stock Analysis, IPO, Mutual Funds, Bonds & More

Buy Lupin, price target Rs 785: Shrikant Chouhan

The analyst suggested a stoploss at Rs 730

ETMarkets.com|
Updated: Dec 13, 2019, 08.17 AM IST
0Comments
ThinkStock Photos
Buy-sale6
Shrikant Chouhan of Kotak Securities Limited has a buy call on Lupin Ltd. with a target price of Rs 785.0 . The current price of Lupin Ltd. is Rs 748.55 Time period given by the analyst is Intra Day when Lupin Ltd. price can reach defined target. Shrikant Chouhan recommended to keep a stoploss at Rs 730 .

Lupin Ltd., incorporated in 1983, has a market cap of Rs 33889.46 crore. Lupin Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 10657.32 Crore to Sales Value (93.84 % of Total Sales), Other Services which contributed Rs 374.24 Crore to Sales Value (3.29 % of Total Sales), Export Incentives which contributed Rs 250.66 Crore to Sales Value (2.20 % of Total Sales) and Other Operating Revenue which contributed Rs 74.10 Crore to Sales Value (0.65 % of Total Sales)for the year ending 31-Mar-2019.

For the quarter ended 30-09-2019, the company has reported a Consolidated sales of Rs 4296.90 Crore, down -1.35 % from last quarter Sales of Rs 4355.83 Crore and up 10.43 % from last year same quarter Sales of Rs 3890.93 Crore Company has reported net profit after tax of Rs -124.40 Crore in latest quarter.

The company’s top management includes Dr.K U Mada, Dr.Kamal K Sharma, Mr.Dileep C Choksi, Mr.Jean-Luc Belingard, Mr.Nilesh Deshbandhu Gupta, Mr.R A Shah, Mr.Richard Zahn, Mrs.Manju D Gupta, Ms.Christine Mundkur, Ms.Vinita Gupta. Company has B S R & Co. LLP as its auditors. As on 30-06-2019, the company has a total of 452,590,752 shares outstanding.

Also Read

Buy Ashok Leyland, price target Rs 86: Shrikant Chouhan

Buy JK Paper, price target Rs 138: Shrikant Chouhan

Buy Amara Raja Batteries, price target Rs 775: Shrikant Chouhan

Buy Granules India, price target Rs 140: Shrikant Chouhan

Buy Dalmia Bharat, price target Rs 858: Shrikant Chouhan

Comments
Add Your Comments
Commenting feature is disabled in your country/region.

Other useful Links


Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service